Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H27FN10 |
Molecular Weight | 498.558 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C=C(C=N1)C2=CN3N=CN=C(N4CCN(CC4)C5=NC=C(C=N5)[C@@](C)(N)C6=CC=C(F)C=C6)C3=C2
InChI
InChIKey=DWYRIWUZIJHQKQ-SANMLTNESA-N
InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1
Molecular Formula | C26H27FN10 |
Molecular Weight | 498.558 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:06:26 UTC 2023
by
admin
on
Sat Dec 16 11:06:26 UTC 2023
|
Record UNII |
513P80B4YJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
506515
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/18/2074
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
||
|
FDA ORPHAN DRUG |
500415
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1703793-34-3
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
PRIMARY | |||
|
Avapritinib
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
PRIMARY | |||
|
118023034
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
PRIMARY | |||
|
DTXSID301027935
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
PRIMARY | |||
|
513P80B4YJ
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
PRIMARY | |||
|
5379
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
PRIMARY | |||
|
DB15233
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
PRIMARY | |||
|
2272107
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
PRIMARY | |||
|
FG-25
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
PRIMARY | |||
|
Avapritinib
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
PRIMARY | |||
|
513P80B4YJ
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
PRIMARY | |||
|
C123827
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
PRIMARY | |||
|
10613
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
PRIMARY | |||
|
100000177408
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
PRIMARY | |||
|
m12190
Created by
admin on Sat Dec 16 11:06:27 UTC 2023 , Edited by admin on Sat Dec 16 11:06:27 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
OFF-TARGET->INHIBITOR |
>100× the free mean maximum plasma concentration at steady state [Cmax,ss] of 0.022 µM at the MTD in humans of 400 mg QD
IC50
|
||
|
METABOLIC ENZYME -> INDUCER |
In vitro, avapritinib is a time-dependent inhibitor as well as an inducer of CYP3A.
|
||
|
EXCRETED UNCHANGED |
Following a single oral dose of approximately 310 mg of radiolabeled avapritinib to healthy subjects
AMOUNT EXCRETED
URINE
|
||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
EXCRETED UNCHANGED |
Following a single oral dose of approximately 310 mg of radiolabeled avapritinib to healthy subjects
AMOUNT EXCRETED
FECAL
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR |
In vitro, avapritinib is a time-dependent inhibitor as well as an inducer of CYP3A.
TIME-DEPENDENT INHIBITION
Ki
|
||
|
METABOLIC ENZYME -> INHIBITOR |
COMPETITIVE INHIBITOR
Ki
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
SINGLE DOSE ADMINISTRATION |
|
||
blood-to-plasma ratio | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
SINGLE DOSE ADMINISTRATION |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||